Meningeosis carcinomatosa als seltener Metastasierungsweg eines BRAF-mutierten Mikrosatelliten-stabilen Kolonkarzinoms

Zusammenfassung

Eine Meningeosis neoplastica ist eine seltene, aber schwerwiegende Komplikation solider Neopasien (Melanome, Mamma-, Bronchial- oder gastrointestinale Karzinome). Die klinische Manifestation der Meningeosis ist äußerst variabel. Sie äußert sich z. B. in radikulären Schmerzen mit oder ohne neurologischen Ausfällen sowie in Kopfschmerzen bis hin zu halluzinatorischen Reizsymptomen. Ob dieses unspezifischen Symptomcharakters wird eine Meningeosis neoplastica häufig zu spät diagnostiziert und behandelt. Wir berichten hier über den seltenen Fall einer Patientin mit einem lymphatisch und ossär metastasierten BRAF-mutierten Mikrosatelliten-stabilen Kolonkarzinom, welche einen Monat nach der Diagnosestellung neurologische Reiz- und Ausfallsymptome entwickelte. Durch den zytologischen Nachweis von Tumorzellen im Liquorsediment konnte – trotz einer unauffälligen MRT-Diagnostik – eine Meningeosis carcinomatosa gesichert werden. Unter einer intrathekalen Therapie mit Methotrexat, kombiniert mit einer intensiven systemischen Antikörperchemotherapie, wurde passager eine gute partielle Remission der Tumorerkrankung erreicht. Ca. 8 Monate nach Therapiebeginn entwickelte jedoch die Patientin eine progrediente Meningeosis und verstarb wenige Wochen später.

Abstract

Leptomeningeal carcinomatosis is a rare but serious complication of solid tumors such as melanoma, breast and lung cancer, as well as gastrointestinal carcinomas. Its clinical manifestation is highly variable, presenting as radicular pain with or without neurological deficits, as well as with headaches and hallucinatory irritation symptoms. Leptomeningeal carcinomatosis is often misdiagnosed, which delays treatment. Here we report a rare case of a patient with BRAF-mutated microsatellite stable colon carcinoma with lymphatic and skeletal metastases, who developed neurological symptoms one month after the initial diagnosis of malignancy. Based on the cytological detection of tumor cells in the cerebrospinal fluid, a leptomeningeal carcinomatosis was diagnosed, despite normal findings on MRI. Intrathecal chemotherapy with methotrexate, combined with intensive systemic immunochemotherapy, resulted in a good partial remission of the underlying malignant disease. However, approximately 8 months after the start of therapy, the patient developed progressive leptomeningeal carcinomatosis and died a few weeks later.

Schlüsselwörter

kolorektales Karzinom - Meningeosis carcinomatosa - BRAFMutation

Key words

colorectal cancer - leptomeningeal carcinomatosis - BRAF mutation

• Literatur

• 1 Von Deimling A, Hattingen E, Hau P. et al. S2k-Leitlinie Hirnmetastasen und Meningeosis neoplastica. AWMF-Registernummer: 030/060
• 2 Assi R, Hamieh L, Mukherji D. et al. Leptomeningeal metastasis as initial manifestation of signet ring colorectal adenocarcinoma: a case report with review of literature. J Gastrointest Oncol 2015; 6: E89-E101
• 3 Giglio P, Weinberg JS, Forman AD. et al. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer 2005; 103: 2355-2362
• 4 Chadha MK, Iyer R, Nava ME. et al. Leptomeningeal metastases from signet ring adenocarcinoma of the cecum. J Clin Oncol 2007; 25: 5028-5029
• 5 Kato Y, Takeda H, Dembo T. et al. Progressive multiple cranial nerve palsies as the presenting symptom of meningeal carcinomatosis from occult colon adenocarcinoma. Intern Med 2012; 51: 795-797
• 6 Lisenko Y, Kumar AJ, Yao J. et al. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol 2003; 26: 165-170
• 7 Cresto N, Barth A, Arnold M. et al. Außergewöhnliche Manifestation eines Magenkarzinoms mit Meningeosis carcinomatosa und spinaler Metastase. Med Klin 2007; 102: 255-258
• 8 Grove A. Meningeal carcinomatosis from a clinically undiagnosed early gastric cancer. Pathol Res Pract 1991; 187: 341-345
• 9 Braeuninger S, Mawrin C, Malfertheiner P. et al. Gastric adenocarcinoma with leptomeningeal carcinomatosis as the presenting manifestation: an autopsy case report. Eur J Gastroenterol Hepatol 2005; 17: 577-579
• 10 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
• 11 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab als first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
• 12 Thiel A, Ristimäki A. Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol 2013; 3: 281
• 13 Atreya CE, Van Cutsem E, Bendell JC. et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol 2015 33. Abstract 103
• 14 Pietrantonio F, Petrelli F, Coinu A. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594
• 15 Rowland A, Dias MM, Wiese MD. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
• 16 Pakneshan S, Salajegheh A, Smith RA. et al. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45: 346-356
• 17 Pai RK, Jayachandran P, Koong AC. et al. BRAF-mutated, mikrosatellitestable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36: 744-752
• 18 Seligmann JF, Fisher D, Smith CG. et al. Exploring the poor outcomes of BRAF mutant advanced colorectal cancer: Analysis from 2530 patients (pts) in randomized clinical trials. Ann Oncol 2017; 28: 562-568
• 19 Glantz MJ, Cole BF, Glantz LK. et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82: 733-739
• 20 Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol 2010; 22: 627-635
• 21 Nakaji Y, Oki E, Nakanishi R. et al. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. J Cancer Res Clin Oncol 2017; 143: 151-160
• 22 Preto A, Figueiredo J, Velho S. et al. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 2008; 214: 320-327
• 23 Kopetz S, McDonough S, Van Karlyle M. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). ASCO GI 2017 Abstr. #520
• 24 Falcone A, Ricci S, Brunetti I. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
• 25 Le D, Uram J, Wang H. et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015; 372: 2509-2520
• 26 Goldberg S, Gettinger S, Mahajan A. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016; 17: 976-983
• 27 Heindel W, Gübitz R, Vieth V. et al. The diagnostic imaging of bone metastases. Dtsch Arztebl Int 2014; 111: 741-747
• 28 Yurgelun M, Allen B, Kaldate R. et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected lynch syndrome. Gastroenterology 2015; 149: 604-613
• 29 Pox C, Aretz S, Bischoff S. et al. S3-guideline colorectal cancer version 1.0. Z Gastroenterol 2013; 51: 753-854